Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18995923 | 0.93 | KDM4E (0.48) | SLC6A7HPGDKDM4EALDH1A1TP53 | |
| SCHEMBL19001365 | 0.84 | SLC6A7 (0.71) | SLC6A7HPGDKDM4EALDH1A1GAA | |
| SCHEMBL18995987 | 0.78 | SLC6A7 (0.64) | SLC6A7HPGDKDM4EALDH1A1GAA | |
| SCHEMBL19001282 | 0.72 | ALDH1A1 (0.69) | SLC6A7HPGDKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL1439167 | 0.71 | KDM4E (0.69) | KDM4EALDH1A1GAATP53L3MBTL1 | |
| SCHEMBL1458671 | 0.69 | ALDH1A1 (0.57) | SLC6A7HPGDKDM4EALDH1A1GAA | |
| SCHEMBL10211172 | 0.68 | HPGD (0.47) | HPGDKDM4EALDH1A1GAANPC1 | |
| SCHEMBL3575539 | 0.68 | SLC6A7 (1.00) | SLC6A7HPGDKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL12639920 | 0.68 | KDM4E (0.72) | KDM4EALDH1A1GAASMN1; SMN2TP53 | |
| SCHEMBL18395354 | 0.68 | KDM4E (0.68) | KDM4EALDH1A1GAATP53L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174704-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174704-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | NAMPT, NQO2, NNMT | SLC6A7 1939/4885HPGD 355/4885KDM4E 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.